Background Reports of waning vaccine-induced immunity against COVID-19 have begun to
surface. With that, the comparable long-term protection conferred by previous infection with …

The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely …

Beyond their substantial protection of individual vaccinees, coronavirus disease 2019 (COVID-19)
vaccines might reduce viral load in breakthrough infection and thereby further …

Importance With the evidence of waning immunity of the mRNA vaccine BNT162b2 (Pfizer-BioNTech),
a nationwide third-dose (booster) vaccination campaign was initiated in Israel …

The effectiveness of the coronavirus disease 2019 (COVID-19) BNT162b2 vaccine in preventing
disease and reducing viral loads of breakthrough infections (BTIs) has been decreasing…

Background Waning of protection against infection with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) conferred by 2 doses of the BNT162b2 vaccine begins shortly …

Mass vaccination has the potential to curb the current COVID-19 pandemic by protecting
individuals who have been vaccinated against the disease and possibly lowering the likelihood …

Background: There is insufficient evidence regarding the magnitude and durability of
protection conferred by a combined effect of naturally acquired immunity after SARS-CoV-2 …

Objective To examine the relative effectiveness of a fourth dose of the Pfizer-BioNTech
mRNA (BNT162b2) vaccine compared with three vaccine doses over the span of 10 weeks. …

The duration of protection of the third (booster) dose of the BioNTech/Pfizer BNT162b2
mRNA Coronavirus Disease 2019 vaccine has been the subject of recent investigations, as …